Global Cancer Monoclonal Antibodies Market 2017-2021

  • ID: 4027557
  • Report
  • Region: Global
  • 115 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • AbbVie
  • AstraZeneca
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Kyowa Hakko Kirin
  • OncoMed Pharmaceuticals
  • MORE
About Cancer Monoclonal Antibodies

The mAbs, which are produced by genetic engineering, target antigens in cells, tissues, and organs. They are used in clinical applications to treat diseases with excellent efficacy and minimal side effects. Their MOA, absence of generic pathway, and therapeutic applications distinguish them from other targeted therapeutics.

The analysts forecast the global cancer monoclonal antibodies market to grow at a CAGR of 10.86% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global cancer monoclonal antibodies market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of branded cancer mAbs and biosimilars used to treat cancer. It also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

- Americas
- APAC
- EMEA

The report, Global Cancer Monoclonal Antibodies Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- F. Hoffmann-La Roche
- Amgen
- Bristol-Myers Squibb
- Takeda Pharmaceuticals

Other prominent vendors
- AbbVie
- ADC Therapeutics
- Agensys
- Argos Therapeutics
- Astellas Pharma
- AstraZeneca
- Bayer
- Biogen
- Biotech Pharmaceutical
- BioGenomics
- Boehringer Ingelheim
- Celldex Therapeutics
- Chugai Pharmaceutical
- CTI BioPharma
- Daiichi Sankyo
- Eli Lilly
- Fortress Biotech
- Genmab
- Immunomedics
- Intas Pharmaceuticals
- Janssen Biotech
- Kyowa Hakko Kirin
- Merck
- MedImmune
- Morphotek
- Neovii Biotech
- Novartis
- OncoMed Pharmaceuticals
- Pfizer
- Sanofi
- Seattle Genetics
- TG Therapeutics
- Xbiotech

Market drivers
- Increase in demand for ADCs
- For a full, detailed list, view the full report

Market challenges
- Complicated regulatory framework
- For a full, detailed list, view the full report

Market trends
- Emergence of targeted and combination therapies
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie
  • AstraZeneca
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Kyowa Hakko Kirin
  • OncoMed Pharmaceuticals
  • MORE
Part 01: Executive summary

Part 02: Scope of the report
  • Market overview
  • Assumptions
  • Top-vendor offerings
Part 03: Market research methodology
  • Research methodology
  • Economic indicators
Part 04: Introduction
  • Key market highlights
Part 05: mAbs: Overview
  • Evolution of mAb therapeutics
  • Conjugated cancer therapies using mAbs
Part 06: Timeline of mAbs for cancer

Part 07: Pipeline portfolio
  • List of Phase III pipeline molecules
  • List of Phase II pipeline molecules
  • List of Phase I pipeline molecules
Part 08: Market landscape
  • Market overview
  • Five forces analysis
Part 09: Market segmentation by type of mAbs
  • Naked mAbs
  • Conjugated mAbs
Part 10: Market segmentation by MOA
  • Immune system suppressors
  • Kill or inhibit malignant cells
  • Angiogenesis inhibitors
  • Radiation therapy to cancer cells
  • Delivering chemotherapy to cancer cells
Part 11: Geographical segmentation
  • Cancer mAbs market in Americas
  • Cancer mAbs market in EMEA
  • Cancer mAbs market in APAC
Part 12: Market drivers
  • Increase in demand for ADCs
  • Special regulatory drug designations
  • Advanced technological innovations
  • Increase in industry-academia collaborations
Part 13: Impact of drivers

Part 14: Market challenges
  • Complicated regulatory framework
  • Absence of adequate diagnosis and screening procedures
  • High manufacturing costs coupled with stringent regulations
  • Threat from chemotherapy and off-label drugs
Part 15: Impact of drivers and challenges

Part 16: Market trends
  • Emergence of targeted and combination therapies
  • Joint ventures and Partnerships for R&D
  • Advent of biosimilars expected to improve the treatment rates
Part 17: Vendor landscape
  • Competitive scenario
  • Key news
  • Other prominent vendors
Part 18: Key vendor analysis
  • Amgen
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Takeda Pharmaceuticals
Part 19: Appendix
  • List of abbreviations
Part 20: About the Author

List of Exhibits

Exhibit 01: Offerings
Exhibit 02: Key buying criteria for cancer mAbs 2016
Exhibit 03: Impact of key customer segments on the market 2016
Exhibit 04: Comparison of small molecule and mAbs
Exhibit 05: Preparation of mAbs
Exhibit 06: Types of mAbs
Exhibit 07: Targeted mechanisms of cancer mAbs
Exhibit 08: Timeline of mAbs for cancer
Exhibit 09: Global cancer mAbs market: Share of pipeline molecules
Exhibit 10: Global cancer mAbs market: Phase III pipeline molecules
Exhibit 11: Global cancer mAbs market: Phase II pipeline molecules
Exhibit 12: Global cancer mAbs market: Phase I pipeline molecules
Exhibit 13: Overview of global cancer mAb market 2016-2021
Exhibit 14: Global cancer mAbs market snapshot: Developed and emerging markets 2016
Exhibit 15: Global cancer mAbs market 2016-2021 ($ billions)
Exhibit 16: A few of patient assistance programs offered by various drugs
Exhibit 17: Few awareness programs for various cancers
Exhibit 18: Patent expiries of top-selling mAbs by 2021 in US
Exhibit 19: Patent expiries of top selling mAbs by 2021 in Europe
Exhibit 20: Annual treatment cost per patient for various oncology drugs 2015
Exhibit 21: Analysis of global cancer mAbs market by type of application
Exhibit 22: Five forces analysis
Exhibit 23: Market share of global cancer mAbs market by type of mAbs:
Exhibit 24: US FDA- and EU-approved naked cancer mAbs
Exhibit 25: Currently available conjugated mAbs
Exhibit 26: Market segmentation by MOA
Exhibit 27: Global cancer mAbs market revenue by geography 2016-2021 ($ billions)
Exhibit 28: Overview of cancer mAbs market in Americas
Exhibit 29: Cancer mAbs market in Americas 2016-2021 ($ billions)
Exhibit 30: Cancer mAb market in Americas: Opportunity analysis
Exhibit 31: Cancer mAbs market in Americas by country 2015
Exhibit 32: Cancer mAbs market in US 2016-2021 ($ billions)
Exhibit 33: Overview of cancer mAbs market in EMEA
Exhibit 34: Cancer mAbs market in EMEA 2016-2021 ($ billions)
Exhibit 35: Cancer mAbs market in EMEA by country 2016
Exhibit 36: Cancer mAb market in EMEA: Opportunity analysis
Exhibit 37: Overview of cancer mAbs market in APAC
Exhibit 38: Cancer mAbs market in APAC 2016-2020 ($ billions)
Exhibit 39: Cancer mAb market in APAC: Opportunity analysis
Exhibit 40: Timeline of ADCs
Exhibit 41: ADC molecules under clinical trials
Exhibit 42: Special regulatory designations approved by US FDA
Exhibit 43: Special regulatory designations approved by EU
Exhibit 44: Advances in ADCs technology
Exhibit 45: Advances in engineered and bispecific antibodies technology
Exhibit 46: Impact of drivers
Exhibit 47: Impact of drivers and challenges
Exhibit 48: Expected combination regimen launches in oncology
Exhibit 49: Market share analysis 2016
Exhibit 50: YoY sales comparison of top cancer mAbs 2013-2015 ($ billions)
Exhibit 51: Competitive assessment of vendors
Exhibit 52: Key vendors: Geographical presence 2015
Exhibit 53: Amgen: Key highlights
Exhibit 54: Amgen: Strength assessment
Exhibit 55: Amgen: Strategy assessment
Exhibit 56: Amgen: Opportunity assessment
Exhibit 57: Bristol-Myers Squibb: Key highlights
Exhibit 58: Bristol-Myers Squibb: Strength assessment
Exhibit 59: Bristol-Myers Squibb: Strategy assessment
Exhibit 60: Bristol-Myers Squibb: Opportunity assessment
Exhibit 61: Hoffmann-La Roche: Key highlights
Exhibit 62: F. Hoffmann-La Roche: Strength assessment
Exhibit 63: F. Hoffmann-La Roche: Strategy assessment
Exhibit 64: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 65: Takeda Pharmaceuticals: Highlights
Exhibit 66: Takeda Pharmaceuticals: Strength assessment
Exhibit 67: Takeda Pharmaceuticals: Strategy assessment
Exhibit 68: Takeda Pharmaceuticals: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AbbVie
  • AstraZeneca
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Kyowa Hakko Kirin
  • OncoMed Pharmaceuticals
  • MORE
New Report Released: - Global Cancer Monoclonal Antibodies Market 2017-2021

The author of the report recognizes the following companies as the key players in the global cancer monoclonal antibodies market: F. Hoffmann-La Roche, Amgen, Bristol-Myers Squibb, and Takeda Pharmaceuticals.

Other Prominent Vendors in the market are: AbbVie, ADC Therapeutics, Agensys, Argos Therapeutics, Astellas Pharma, AstraZeneca, Bayer, Biogen, Biotech Pharmaceutical, BioGenomics, Boehringer Ingelheim, Celldex Therapeutics, Chugai Pharmaceutical, CTI BioPharma, Daiichi Sankyo, Eli Lilly, Fortress Biotech, Genmab, Immunomedics, Intas Pharmaceuticals, Janssen Biotech, Kyowa Hakko Kirin, Merck, MedImmune, Morphotek, Neovii Biotech, Novartis, OncoMed Pharmaceuticals, Pfizer, Sanofi, Seattle Genetics, TG Therapeutics, and Xbiotech.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is emergence of targeted and combination therapies. Targeted and combination therapies are being increasingly developed for the treatment of cancers and inflammatory diseases. These therapies, which exploit the surface markers or properties of diseased or infected cells, cause fewer adverse side effects than conventional non-targeted therapies.”

According to the report, one of the major drivers for this market is increase in demand for ADCs. Antibodies are increasingly becoming the preferred choice to treat diseases such as respiratory, oncology, and inflammatory diseases. Understanding diseases at a molecular level increases the development and use of antibodies. The use of ADCs, including radioimmunotherapy and antibody-directed enzyme prodrug therapy, is growing. The increasing use of these antibodies in drug development increases revenue generation in the global next-generation biologics market, thereby contributing to the cancer mAbs market growth.

Further, the report states that one of the major factors hindering the growth of this market is complicated regulatory framework. Gaining regulatory approval is often difficult, unpredictable, and subjective. Biologics products must undergo a broad range of stringent regulations before approval and commercialization. Currently, the US FDA has approved very few products for stem cell therapy. However, there are several transplant centers running in the region that uses unapproved cell therapies.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • F. Hoffmann-La Roche
  • Amgen
  • Bristol-Myers Squibb
  • Takeda Pharmaceuticals
  • AbbVie
  • ADC Therapeutics
  • Agensys
  • Argos Therapeutics
  • Astellas Pharma
  • AstraZeneca
  • Bayer
  • Biogen
  • Biotech Pharmaceutical
  • BioGenomics
  • Boehringer Ingelheim
  • Celldex Therapeutics
  • Chugai Pharmaceutical
  • CTI BioPharma
  • Daiichi Sankyo
  • Eli Lilly
  • Fortress Biotech
  • Genmab
  • Immunomedics
  • Intas Pharmaceuticals
  • Janssen Biotech
  • Kyowa Hakko Kirin
  • Merck
  • MedImmune
  • Morphotek
  • Neovii Biotech
  • Novartis
  • OncoMed Pharmaceuticals
  • Pfizer
  • Sanofi
  • Seattle Genetics
  • TG Therapeutics
  • Xbiotech
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll